Anti-VEGF Archives

May 23, 2025

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

Genentech/Roche’s sustained release anti-VEGF eye implant provides a treatment option with reduced frequency for diabetic retinopathy. Sustained release anti-VEGF is…

FDA Rejects Regeneron’s Bid to Extend EYLEA HD Dosing Beyond 16 Weeks

April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Regeneron’s proposal to lengthen EYLEA HD dosing intervals to 24 weeks hits a CRL roadblock. The wait for extended treatment…

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

April 22, 2025

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

z4889203089827_b383d19bbac9759a10fd0883c30c5733

November 17, 2023

Geeking Out on Gels and Nanos: Move over, anti-VEGF and lasers! There’s a new cool posterior segment tech in town!

November 17, 2023

A REVOLUTION in Retinal Therapies: From anti-VEGF to TKIs and gene therapy, cutting-edge innovations are changing the landscape of medical retina

October 7, 2023

Going Hybrid: Could combination therapy be the solution for patients with anti-VEGF-resistant AMD?

One out unique pineapple wearing headphones

March 16, 2020

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

FDA Approves Roche’s Susvimo for Diabetic Retinopathy

FDA Rejects Regeneron’s sBLA to Extend EYLEA HD Dosing Interval

Geeking Out on Gels and Nanos: Move over, anti-VEGF and lasers! There’s a new cool posterior segment tech in town!

A REVOLUTION in Retinal Therapies: From anti-VEGF to TKIs and gene therapy, cutting-edge innovations are changing the landscape of medical retina

Going Hybrid: Could combination therapy be the solution for patients with anti-VEGF-resistant AMD?

What’s the Buzz on Anti-VEGF Biosimilars?

Discover our fascinating content at issuu